To kill a tumor cell: the potential of proapoptotic receptor agonists

被引：265

作者：

Ashkenazi, Avi ^{[1
]}

Herbst, Roy S. ^{[2
,3
]}

机构：

[1] Genentech Inc, Dept Mol Oncol, San Francisco, CA 94080 USA

[2] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA

[3] Univ Texas MD Anderson Canc Ctr, Dept Canc Biol, Houston, TX 77030 USA

来源：

JOURNAL OF CLINICAL INVESTIGATION | 2008年 / 118卷 / 06期

关键词：

D O I：

10.1172/JCI34359

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Disturbances in mechanisms that direct abnormal cells to undergo apoptosis frequently and critically contribute to tumorigenesis, yielding a logical target for potential therapeutic intervention. There is currently heightened interest in the extrinsic apoptosis pathway, with several proapoptotic receptor agonists (PARAs) in development. The PARAs include the ligand recombinant human Apo2L/TRAIL and agonistic mAbs. Mechanistic and preclinical data with Apo2L/TRAIL indicate exciting opportunities for synergy with conventional therapies and for combining PARAs with other molecularly targeted agents. Novel molecular biomarkers may help identify those patients most likely to benefit from PARA therapy.

引用

页码：1979 / 1990

页数：12

共 130 条

[1] Structural and functional analysis of the interaction between the agonistic monoclonal antibody Apomab and the proapoptotic receptor DR5 [J].

Adams, C. ;

Totpal, K. ;

Lawrence, D. ;

Marsters, S. ;

Pitti, R. ;

Yee, S. ;

Ross, S. ;

Deforge, L. ;

Koeppen, H. ;

Sagolla, M. ;

Compaan, D. ;

Lowman, H. ;

Hymowitz, S. ;

Ashkenazi, A. .

CELL DEATH AND DIFFERENTIATION, 2008, 15 (04) :751-761

[2] Safety and antitumor activity of recombinant soluble Apo2 ligand [J].

Ashkenazi, A ;

Pai, RC ;

Fong, S ;

Leung, S ;

Lawrence, DA ;

Masters, SA ;

Blackie, C ;

Chang, L ;

McMurtrey, AE ;

Hebert, A ;

DeForge, L ;

Koumenis, IL ;

Lewis, D ;

Harris, L ;

Bussiere, J ;

Koeppen, H ;

Shahrokh, Z ;

Schwall, RH .

JOURNAL OF CLINICAL INVESTIGATION, 1999, 104 (02) :155-162

[3] Targeting death and decoy receptors of the tumour-necrosis factor superfamily [J].

Ashkenazi, A .

NATURE REVIEWS CANCER, 2002, 2 (06) :420-430

[4]

ATTARD G, 2005, AACR NCI EORTC INT C

[5] Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: The oblimersen melanoma study group [J].

Bedikian, Agop Y. ;

Millward, Michael ;

Pehamberger, Hubert ;

Conry, Robert ;

Gore, Martin ;

Trefzer, Uwe ;

Pavlick, Anna C. ;

DeConti, Ronald ;

Hersh, Evan M. ;

Hersey, Peter ;

Kirkwood, John M. ;

Haluska, Frank G. .

JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4738-4745

[6]

BONOMI P, 2005, 11 WORLD C LUNG CANC

[7] Cell death independent of caspases:: A review [J].

Bröker, LE ;

Kruyt, FAE ;

Giaccone, G .

CLINICAL CANCER RESEARCH, 2005, 11 (09) :3155-3162

[8] The proteasome inhibitor bortezomib (Velcade) sensitizes some human tumor cells to Apo2L/TRAIL-mediated apoptosis [J].

Brooks, AD ;

Ramirez, T ;

Toh, U ;

Onksen, J ;

Elliott, PJ ;

Murphy, WJ ;

Sayers, TJ .

TUMOR PROGRESSION AND THERAPEUTIC RESISTANCE, 2005, 1059 :160-167

[9]

CAMIDGE DR, 2007, P AN M AM SOC CLIN, V25, P3582

[10]

CHOW LQ, 2006, P AN M AM SOC CLIN, V24, P2525

← 1 2 3 4 5 6 7 8 9 10 →